Imagine being denied a potentially life-saving cancer treatment simply because of where you live. This is the harsh reality for many cancer patients in England, caught in what doctors call a 'deadly postcode lottery'. But here's where it gets even more frustrating: these treatments aren't experimental – they're proven effective and widely available in other countries. Two groundbreaking radiotherapy techniques, stereotactic ablative body radiotherapy (SABR) and molecular radiotherapy (MRT), are being held back by a tangled web of 'red tape' and funding shortages within the NHS.
The Royal College of Radiologists (RCR) and Radiotherapy UK are urging Health Secretary Wes Streeting to use the government's upcoming cancer plan to break this deadlock. They argue that the NHS's complex funding and commissioning processes create unnecessary 'bureaucratic hurdles' for hospitals wanting to offer these life-changing treatments.
And this is the part most people miss: It's not just about SABR and MRT. The same red tape means only half of England's cancer centers can provide surface-guided radiation therapy (SGRT), a technology that uses real-time 3D imaging to make treatment more precise and reduce long-term damage to healthy organs like the heart. Even when hospitals do have the equipment, it's often thanks to local charities footing the £250,000 bill, not the NHS.
Dr. Nicky Thorp, RCR's vice-president for clinical oncology, paints a stark picture: 'We have treatments that we know work, that could mean fewer doses and fewer side effects for our patients, but they're simply not accessible to everyone.'
Professor Pat Price, chair of Radiotherapy UK, highlights the tragic irony: 'We know how to improve our cancer survival rates, which are embarrassingly low compared to other countries. But bureaucracy and a broken funding system are holding us back.'
Price points out that SABR and SGRT are routinely used elsewhere, leading to more cures, more precise treatments, and shorter waiting lists.
Here's the controversial bit: The NHS's 'tariff' system, which dictates how hospitals are paid for treatments, is outdated. Hospitals actually lose money if they use SABR for cancers other than lung cancer, even though evidence shows it's effective for liver, prostate, and kidney cancers too. This means patients who could benefit are often forced to seek treatment privately.
Cancer Research UK has been sounding the alarm for years, linking these inequalities in access to the UK's lagging cancer survival rates. They also highlight the knock-on effect of outdated radiotherapy machines, still in use due to lack of NHS funding, which further contributes to growing waiting lists.
NHS England assures us the upcoming cancer plan will address these issues, promising wider availability of innovative treatments. But will it be enough to end this postcode lottery and give all cancer patients a fair chance at survival?
What do you think? Is the NHS doing enough to ensure equal access to life-saving cancer treatments? Let us know in the comments.
